Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)

Tsutomu Takeuchi; Yoshiya Tanaka; Sakae Tanaka; Atsushi Kawakami; Yeong Wook Song; Yi Hsing Chen; Mitsuhiro Rokuda; Hiroyuki Izutsu; Satoshi Ushijima; Yuichiro Kaneko; Yoshihiro Nakashima; Teruaki Shiomi; Emi Yamada

doi:10.1186/s13075-020-02247-3

Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)

Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong Wook Song, Yi Hsing Chen, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Yoshihiro Nakashima, Teruaki Shiomi, Emi Yamada

Vice-President

Research output: Contribution to journal › Comment/debate

Abstract

Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c. The CI numbers in the table below the graph are correct, but the upper and lower limit bars plotted on the graph are incorrect. The corrected Fig. 6 is given below.

Original language	English
Article number	155
Journal	Arthritis Research and Therapy
Volume	22
Issue number	1
DOIs	https://doi.org/10.1186/s13075-020-02247-3
Publication status	Published - 2020 Jun 23

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.1186/s13075-020-02247-3

Fingerprint Dive into the research topics of 'Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)'. Together they form a unique fingerprint.

Cite this

Takeuchi, T., Tanaka, Y., Tanaka, S., Kawakami, A., Song, Y. W., Chen, Y. H., Rokuda, M., Izutsu, H., Ushijima, S., Kaneko, Y., Nakashima, Y., Shiomi, T., & Yamada, E. (2020). Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2). Arthritis Research and Therapy, 22(1), [155]. https://doi.org/10.1186/s13075-020-02247-3

Erratum : Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2). / Takeuchi, Tsutomu; Tanaka, Yoshiya; Tanaka, Sakae; Kawakami, Atsushi; Song, Yeong Wook; Chen, Yi Hsing; Rokuda, Mitsuhiro; Izutsu, Hiroyuki; Ushijima, Satoshi; Kaneko, Yuichiro; Nakashima, Yoshihiro; Shiomi, Teruaki; Yamada, Emi.

In: Arthritis Research and Therapy, Vol. 22, No. 1, 155, 23.06.2020.

Research output: Contribution to journal › Comment/debate

Takeuchi, T, Tanaka, Y, Tanaka, S, Kawakami, A, Song, YW, Chen, YH, Rokuda, M, Izutsu, H, Ushijima, S, Kaneko, Y, Nakashima, Y, Shiomi, T & Yamada, E 2020, 'Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)', Arthritis Research and Therapy, vol. 22, no. 1, 155. https://doi.org/10.1186/s13075-020-02247-3

Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song YW, Chen YH et al. Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2). Arthritis Research and Therapy. 2020 Jun 23;22(1). 155. https://doi.org/10.1186/s13075-020-02247-3

Takeuchi, Tsutomu ; Tanaka, Yoshiya ; Tanaka, Sakae ; Kawakami, Atsushi ; Song, Yeong Wook ; Chen, Yi Hsing ; Rokuda, Mitsuhiro ; Izutsu, Hiroyuki ; Ushijima, Satoshi ; Kaneko, Yuichiro ; Nakashima, Yoshihiro ; Shiomi, Teruaki ; Yamada, Emi. / Erratum : Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2). In: Arthritis Research and Therapy. 2020 ; Vol. 22, No. 1.

@article{bb3d1af7a206499fb0b8289e8ae6249f,

title = "Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)",

abstract = "Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c. The CI numbers in the table below the graph are correct, but the upper and lower limit bars plotted on the graph are incorrect. The corrected Fig. 6 is given below.",

author = "Tsutomu Takeuchi and Yoshiya Tanaka and Sakae Tanaka and Atsushi Kawakami and Song, {Yeong Wook} and Chen, {Yi Hsing} and Mitsuhiro Rokuda and Hiroyuki Izutsu and Satoshi Ushijima and Yuichiro Kaneko and Yoshihiro Nakashima and Teruaki Shiomi and Emi Yamada",

year = "2020",

month = jun,

day = "23",

doi = "10.1186/s13075-020-02247-3",

language = "English",

volume = "22",

journal = "Arthritis Research and Therapy",

issn = "1478-6354",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Erratum

T2 - Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)

AU - Takeuchi, Tsutomu

AU - Tanaka, Yoshiya

AU - Tanaka, Sakae

AU - Kawakami, Atsushi

AU - Song, Yeong Wook

AU - Chen, Yi Hsing

AU - Rokuda, Mitsuhiro

AU - Izutsu, Hiroyuki

AU - Ushijima, Satoshi

AU - Kaneko, Yuichiro

AU - Nakashima, Yoshihiro

AU - Shiomi, Teruaki

AU - Yamada, Emi

PY - 2020/6/23

Y1 - 2020/6/23

N2 - Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c. The CI numbers in the table below the graph are correct, but the upper and lower limit bars plotted on the graph are incorrect. The corrected Fig. 6 is given below.

AB - Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c. The CI numbers in the table below the graph are correct, but the upper and lower limit bars plotted on the graph are incorrect. The corrected Fig. 6 is given below.

UR - http://www.scopus.com/inward/record.url?scp=85087003304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087003304&partnerID=8YFLogxK

U2 - 10.1186/s13075-020-02247-3

DO - 10.1186/s13075-020-02247-3

M3 - Comment/debate

C2 - 32576246

AN - SCOPUS:85087003304

VL - 22

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 1

M1 - 155

ER -